Cisplatin/Carboplatin

DRUG16 trials

Sponsors

Fudan University Shanghai Cancer Center, Dr Shivendra Singh, Merck KGaA, Darmstadt, Germany, Genentech, Inc., Grupo Español de Investigación en Cáncer de Ovario

Conditions

Advanced NSCLCAdvanced cervical cancerBreast CancerCarcinoma of the Cervix, Stage IVBCarcinoma, Squamous Cell of Head and NeckCervical CancerHead and Neck Squamous Cell CarcinomaHealth Condition 1: null- Patients with resectable Carcinoma Gastroesophageal junction without clinical metastasis

Phase 1

IBI188 Combination Therapy in Solid Tumors

TerminatedNCT04861948

Innovent Biologics (Suzhou) Co. Ltd.Lung Adenocarcinoma, Osteosarcoma, Solid Tumors

Start: 2021-05-25End: 2022-07-30Updated: 2022-10-04

Phase 2

Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

CompletedNCT00971932

Merck KGaA, Darmstadt, GermanySquamous Cell Carcinoma of the Head and Neck

Start: 2009-07-31Updated: 2014-04-08

A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer

CompletedNCT01496742

Genentech, Inc.Non-Squamous Non-Small Cell Lung Cancer

Start: 2012-04-30End: 2015-11-30Updated: 2016-09-23

A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer

CompletedNCT01519804

Genentech, Inc.Non-Squamous Non-Small Cell Lung Cancer

Start: 2012-04-30End: 2015-09-30Updated: 2016-09-02

Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors

Shanghai Henlius BiotechHead and Neck Squamous Cell Carcinoma

Start: 2020-07-29End: 2025-06-30Target: 131Updated: 2023-08-08

A Phase II Study of Triple-negative Breast Cancer Brain Metastases.

RecruitingNCT04303988

Fudan UniversityBreast Cancer

Start: 2020-03-30End: 2025-05-30Target: 35Updated: 2024-07-18

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Taizhou Hanzhong biomedical co. LTDNonsquamous Non-small Cell Lung Cancer

Start: 2020-09-25End: 2023-09-25Target: 700Updated: 2021-02-11

QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer

TerminatedNCT04864782

Qilu Pharmaceutical Co., Ltd.Cervical Cancer

Start: 2020-09-23End: 2023-11-01Updated: 2024-01-12

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

Active, not recruitingNCT05609578

Mirati Therapeutics Inc.Advanced NSCLC, Metastatic Lung Cancer

Start: 2022-11-22End: 2026-12-01Target: 90Updated: 2026-06-23

Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma

Active, not recruitingNCT06318286

Hyogo Medical UniversityMalignant Pleural Mesothelioma

Start: 2024-03-13End: 2026-10-30Target: 25Updated: 2026-06-10

Phase 3

Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer

CompletedNCT02383966

Merck KGaA, Darmstadt, GermanyCarcinoma, Squamous Cell of Head and Neck

Start: 2015-07-31End: 2021-12-20Updated: 2022-05-13

Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix

CompletedNCT03556839

Grupo Español de Investigación en Cáncer de OvarioCarcinoma of the Cervix, Stage IVB

Start: 2018-09-25End: 2025-08-31Updated: 2026-04-21

QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

Qilu Pharmaceutical Co., Ltd.METASTATIC CERVICAL CANCER

Start: 2022-09-23End: 2025-07-01Target: 498Updated: 2022-11-30

9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

RecruitingNCT06592326

Mabwell (Shanghai) Bioscience Co., Ltd.Urothelial Carcinoma

Start: 2024-08-22End: 2028-12-31Target: 460Updated: 2024-09-19

A randomized, controlled, double-blind, multicenter phase III clinical study of Adebrelimab combined with concurrent chemoradiotherapy versus placebo combined with concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer

Active, not recruitingChiCTR2600125844

Fudan University Shanghai Cancer CenterAdvanced cervical cancer

Start: 2026-06-11Updated: 2026-06-08

Unknown Phase

Therapy for Cancer at Stomach and Esophagous junction

RecruitingCTRI/2018/05/013757

Dr Shivendra SinghHealth Condition 1: null- Patients with resectable Carcinoma Gastroesophageal junction without clinical metastasis

Target: 50Updated: 2021-11-24

Related Papers

Bulumtatug fuvedotin (BFv; 9MW2821) plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): Follow-up results from a phase 1b/2 study.

Journal of Clinical Oncology2026-05-27

Cost-effectiveness analysis of first-line treatments for recurrent or metastatic head and neck cancer in China: an economic evaluation based on network meta-analysis

Frontiers in Pharmacology2025-09-29

Population Pharmacokinetics and Exposure–Response Analysis of Serplulimab in Small Cell Lung Cancer Patients

Clinical and Translational Science2025-09-01

A phase II clinical study of adebrelimab and bevacizumab combined with cisplatin/carboplatin in triple-negative breast cancer patients with brain metastases.

Journal of Clinical Oncology2025-05-28

Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study.

2025-04-258 citations

Abstract CT209: Adagrasib (ADA) as first-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring <i>KRAS</i>G12Cand <i>STK11</i> mutations: KRYSTAL-1 phase 2 cohort

Cancer Research2025-04-25

Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATcc

Journal of Gynecologic Oncology2025-01-01

A phase II trial combining SHR-1316, bevacizumab, and cisplatin/carboplatin in patients with TNBC with active brain metastases.

Journal of Clinical Oncology2024-06-013 citations

251 Efficacy and safety of iparomlimab and tuvonralimab in previously treated patients with recurrent or metastatic cervical cancer: a multicenter, open-label, single-arm, phase 2 clinical trial (DUBHE-C-206)

2024-03-014 citations

427 BEATcc (ENGOT-CX10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase 3 trial of first-line atezolizumab with bevacizumab and platinum-based chemotherapy for metastatic (stage IVB), persistent or recurrent cervical cancer

2024-03-013 citations

Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer

Clinical Cancer Research2024-01-028 citations

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.

2023-12-01127 citations

A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti–PD-1 mAb, in patients with advanced or metastatic solid tumors

Frontiers in Immunology2023-10-233 citations

First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors

Journal of Hematology & Oncology2023-05-0839 citations

First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial.

2021-08-1831 citations

A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).

2019-10-2358 citations

BEATcc (ENGOT-Cx10/GEICO 68-C/GOG3030/JGOG1084): A randomized, open label, phase III study of cisplatin and paclitaxel chemotherapy with bevacizumab (CTx plus B) with or without atezolizumab (Atz) as first-line treatment for metastatic, persistent, or recurrent (m/r) carcinoma of the cervix (CCx).

Journal of Clinical Oncology2019-05-206 citations